DOCSLIB.ORG

A Systematic Review of Venous Thromboembolism Prophylaxis Strategies in Patients with Renal Insufficiency, Obesity, Or on Antiplatelet Agents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Systematic Review of Venous Thromboembolism Prophylaxis Strategies in Patients with Renal Insufficiency, Obesity, Or on Antiplatelet Agents REVIEWS A Systematic Review of Venous Thromboembolism Prophylaxis Strategies in Patients With Renal Insufficiency, Obesity, or on Antiplatelet Agents Sosena Kebede, MD, MPH1*, Kalpana R. Prakasa, MBBS, MS1, Kenneth Shermock, PharmD, PhD1,2, Hasan M. Shihab, MBChB, MPH2, Daniel J. Brotman, MD1, Ritu Sharma, BSc2, Yohalakshmi Chelladurai, MBBS, MPH2, Elliott R. Haut, MD3, Sonal Singh, MD, MPH1,2, Jodi B. Segal, MD, MPH1,2 1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; 2Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 3Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. BACKGROUND: There is uncertainty about optimal strat- RESULTS: After a review of 30,902 citations, we identified 9 egies for venous thromboembolism (VTE) prophylaxis among controlled studies, 5 of which were trials, and the other 4 select populations such as patients with renal insufficiency, were observational studies. Five articles addressed prophy- obesity, or patients taking antiplatelet drugs including aspirin. laxis of patients with renal insufficiency, 2 addressed obese Their physiologies make prophylaxis particularly challenging. patients, and 2 addressed patients on antiplatelet agents. No study tested prophylaxis in underweight patients or PURPOSE: We performed a comparative effectiveness those with liver disease. The majority of observational review of the literature on efficacy and safety of VTE pro- studies had a high risk of bias. The strength of evidence phylaxis in these populations. ranged from low to insufficient regarding the comparative DATA SOURCES: We searched MEDLINE, EMBASE, SCO- effectiveness and safety of VTE prophylaxis among these PUS, CINAHL, International Pharmaceutical Abstracts, clini- patients. caltrial.gov, and the Cochrane Library through August 2012. CONCLUSION: The current evidence is insufficient regard- Eligible studies included controlled trials and observational ing optimal VTE prophylaxis for patients with renal insuffi- studies. ciency, obesity, or those who are on antiplatelet drugs DATA EXTRACTION: Two reviewers evaluated studies for including aspirin. High-quality studies are needed to inform eligibility, serially abstracted data, and independently eval- clinicians about the best VTE prophylaxis for these patients. uated the risk of bias and strength of evidence supporting Journal of Hospital Medicine 2013;8:394–401. VC 2013 interventions to prevent VTE in these populations. Society of Hospital Medicine Venous thromboembolism (VTE), including deep ve- also at high risk of bleeding, the most important com- nous thrombosis (DVT) and pulmonary embolism plication of VTE prophylaxis.3–6 (PE), is estimated to affect 900,000 Americans each The objectives of this systematic review were to year and is a cause of significant morbidity and mor- define the comparative effectiveness and safety of tality with associated high healthcare costs.1 Accord- pharmacologic and mechanical strategies for VTE pre- ingly, the comparative effectiveness and safety of vention in some of these select medical populations interventions for the prevention and treatment of VTE including obese patients, patients on concomitant anti- are among the national priorities for comparative platelet therapy, patients with renal insufficiency, effectiveness research.2 Whereas we have evidence- patients who are underweight, and patients with coa- based guidelines for the prophylaxis of VTE in the gulopathy due to liver disease. general population, there are no guidelines informing the care of select patient populations. Select popula- METHODS tions are those patients in whom there is decisional The methods for this comparative effectiveness review uncertainty about the optimal choice, timing, and (CER) follow the guidelines suggested in the Agency dose of VTE prophylaxis. Not only do these patients for Healthcare Research and Quality (AHRQ) have an increased risk of DVT and PE, but most are Methods Guide for Effectiveness and Comparative Effectiveness Reviews.7 The protocol was publically posted.8 *Address for correspondence and reprint requests: Sosena Kebede, MD, MPH, Department of Medicine, 600 North Wolfe Street, Nelson 215, Baltimore, MD 21287; Telephone: 443-287-4538; Fax: 410–502-0923; Search Strategy E-mail: [email protected] We searched MEDLINE, EMBASE, and SCOPUS Additional Supporting Information may be found in the online version of through August 2011, CINAHL, International Phar- this article. maceutical Abstracts, clinicaltrial.gov, and the Received: January 11, 2013; Revised: March 13, 2013; Accepted: Cochrane Library through August 2012. We devel- March 19, 2013 2013 Society of Hospital Medicine DOI 10.1002/jhm.2047 oped a search strategy based on medical subject head- Published online in Wiley Online Library (Wileyonlinelibrary.com). ings (MeSH) terms and text words of key articles that 394 An Official Publication of the Society of Hospital Medicine Journal of Hospital Medicine Vol 8 | No 7 | July 2013 Review of VTE Prophylaxis Strategies | Kebede et al we identified a priori9 (see the Appendix for search diagnoses prompting hospitalization were congestive strategy details). heart failure, respiratory failure, and infectious dis- eases. Compression ultrasound was performed in all Study Selection patients by day 21 of hospitalization. The primary We reviewed titles followed by abstracts to identify end point was the composite of VTE, fatal PE, and randomized controlled trials (RCTs) or observational sudden death, and secondary end points included studies with comparison groups reporting on the effec- DVT, bleeding, and thrombocytopenia by day 21 tiveness or safety of VTE prevention in our popula- (Table 1). In obese patients, the primary end point tions. Two investigators independently reviewed occurred in 2.8% (95% confidence interval [CI]: 1.3– abstracts, and we excluded the abstracts if both inves- 4.3) of the dalteparin group and in 4.3% (95% CI: tigators agreed that the article met 1 or more of the 2.5–6.2) of the placebo group (relative risk [RR]: exclusion criteria. We included only English-language 0.64; 95% CI: 0.32-1.28). In nonobese patients, the articles that evaluated the effectiveness of pharmaco- primary end point occurred in 2.8% (95% CI: 1.8- logical or mechanical interventions that have been 3.8) and 5.2% (95% CI: 3.9-6.6) of the dalteparin approved for clinical use in the United States. To be and placebo groups, respectively (RR: 0.53; 95% CI: eligible, the studies must have addressed relevant key 0.34-0.82). When weight was modeled as a continu- questions in the population of our interest. We ous variable, no statistically significant interaction resolved disagreements by consensus. We used Distill- between weight and dalteparin efficacy was observed erSR (Evidence Partners Inc., Ottawa, Ontario, Can- (P 5 0.97). The authors calculated the RR in prede- ada), a Web-based database management program to fined BMI subgroups and found that dalteparin was manage the review process. Two investigators assessed effective in reducing VTE in patients with BMIs up to the risk of bias in each study independently, using the 40, with RRs of <1.0 for all (approximate range, 0.2– Downs and Black instrument for observational studies 0.8). However, a fixed dose of dalteparin 5000 IU/day 10 and trials. was not better than placebo for individuals with BMI > 2 Data Synthesis 40 kg/m . There was no significant difference in mortality or major hemorrhage by day 21 between For each select population, we created detailed evi- treatment and placebo groups. dence tables containing the information abstracted Freeman and colleagues prospectively assigned 31 from the eligible studies. After synthesizing the evi- medically ill patients with extreme obesity (BMI >40 dence, we graded the quantity, quality, and consis- kg/m2) to 1 of 3 dosing regimens of enoxaparin: a tency of the best available evidence for each select fixed dose of 40 mg daily enoxaparin (control group, population by adapting an evidence-grading scheme n 5 11), enoxaparin at 0.4 mg/kg (n 5 9), or enoxa- recommended in the Methods Guide for Conducting parin at 0.5 mg/kg (n 5 11).12 The average BMI of the Comparative Effectiveness Reviews.7 entire cohort was 62.1 kg/m2 (range, 40.5–82.4). All RESULTS patients had anti-factor Xa levels drawn on the day of We identified 30,902 unique citations and included 9 enrollment and daily for 3 days (Table 2). The rela- studies (Figure 1). There were 5 RCTs with relevant tionship between anti-factor Xa levels and clinical effi- subgroups and 4 observational studies (Table 1). Two cacy of low-molecular weight heparin (LMWH) in studies reported on the risk of bleeding in patients VTE prophylaxis is still unclear; however, an anti- given pharmacologic prophylaxis while they are con- factor Xa level of 0.2 to 0.5 IU/mL, measured 4 hours comitantly taking nonsteroidal anti-inflammatory after the fourth dose of LMWH, is the target level rec- 13 drugs (NSAIDS) or antiplatelet agents/aspirin, 1 RCT ommended for VTE prophylaxis. Patients who and 1 prospective observational study reported on received weight-based enoxaparin at 0.5 mg/kg obese patients, and 5 studies described outcomes of achieved target anti-factor Xa level 86% of the time patients with renal insufficiency (see Supporting Infor- compared to 32% of the time in those receiving 0.4 mation, Table 1, in the online version of this article). mg/kg and 19% of the time for those in the fixed-dose No study tested prophylaxis in underweight patients group (P < 0.001). No clinical outcomes were or those with liver disease. reported in this study. Obese Patients Patients on Antiplatelet Drugs We found 1 subgroup analysis of an RCT (total 3706 We did not find studies that directly looked at the patients, 2563 nonobese and 1118 obese patients) that comparative effectiveness of VTE prophylaxis in reported on the comparative effectiveness and safety patients who were on antiplatelet drugs including as- of fixed low-dose dalteparin 5000 IU/day compared to pirin.
Load more

Recommended publications
  • Occurrence, Elimination, and Risk of Anticoagulant Rodenticides in Wastewater and Sludge
    Occurrence, elimination, and risk of anticoagulant rodenticides in wastewater and sludge Silvia Lacorte, Cristian Gómez- Canela Department of Environmental Chemistry, IDAEA-CSIC, Jordi Girona 18-26, 08034 Barcelona Rats and super-rats Neverending story 1967 Coumachlor 1 tn rodenticides /city per campaign “It will be the LAST ONE” Rodenticides Biocides: use regulated according to EU. Used mainly as bait formulations. First generation: multiple feedings, less persistent in tissues, commensal and outdoor use. Second generation: single feeding (more toxic), more persistent in tissue, commensal use only. Toxic: vitamin K antagonists that cause mortality by blocking an animal’s ability to produce several key blood clotting factors. High oral, dermal and inhalation toxicity. Origin and fate of rodenticides Study site: Catalonia (7.5 M inhabitants) 1693 km of sewage corridor 13 fluvial tanks (70.000 m3) 130,000,000 € / 8 YEARS 32,000 km2 378,742 kg/y AI 2,077,000 € Objectives 1. To develop an analytical method to determine most widely used rodenticides in wastewater and sludge. 2. To monitor the presence of rodenticides within 9 WWTP receiving urban and agricultural waters. 3. To evaluate the risk of rodenticides using Daphnia magna as aquatic toxicological model. 4. To study the accumulation of rodenticides in sludge. Compounds studied Coumachlor* Pindone C19H15ClO4 C14H14O3 Dicoumarol Warfarin C19H12O6 C19H16O4 Coumatetralyl Ferulenol FGARs C19H16O3 C24H30O3 Acenocoumarol Chlorophacinone • Solubility C19H15NO6 C23H15ClO3 0.001-128 mg/L • pKa 3.4-6.6 Flocoumafen Bromadiolone C H F O C H BrO 33 25 3 40 30 23 4 • Log P 1.92-8.5 Brodifacoum Fluindione C H BrO 31 23 3 C15H9FO2 SGARs Difenacoum Fenindione C31H24O3 C15H10O2 1.
    [Show full text]
  • Package Leaflet: Information for the User Innohep® 10,000 IU/Ml Solution for Injection Tinzaparin Sodium
    Package leaflet: Information for the user innohep® 10,000 IU/ml solution for injection tinzaparin sodium Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. • In this leaflet innohep 10,000 IU/ml will be called innohep. What is in this leaflet 1. What innohep® is and what it is used for 2. What you need to know before you use innohep® 3. How to use innohep® 4. Possible side effects 5. How to store innohep® 6. Contents of the pack and other information 1. What innohep® is and what it is used for innohep is a type of heparin – a low molecular weight heparin – and belongs to a group of medicines called anticoagulants; these medicines affect how your blood clots. innohep prevents clotting, allowing normal blood flow through the arteries and veins. innohep is used to: Prevent blood clots in adults before and after an operation. Prevent blood clots in adults who have an increased risk of blood clots e.g. due to an acute illness with limited mobility. Prevent blood clots being formed in haemodialysis equipment in patients undergoing haemodialysis or haemofiltration.
    [Show full text]
  • SPECIALTY MEDICATIONS Available Through Accredo Health Group, Inc., Medco’S Specialty Pharmacy Call Toll-Free (800) 803-2523, 8:00 A.M
    SPECIALTY MEDICATIONS available through Accredo Health Group, Inc., Medco’s specialty pharmacy Call toll-free (800) 803-2523, 8:00 a.m. to 8:00 p.m., eastern time, Monday through Friday, to confirm that your medication is covered. Effective as of July 1, 2011 Abraxane® (paclitaxel protein-bound particles) Berinert® (C 1 esterase inhibitor [human])* (PA) (QD) Actemra ™ (tocilizumab) (PA) Betaseron® (interferon beta-1b) (PA) Actimmune® (interferon gamma-1b) (PA) Botox® (botulinum toxin type A) (PA) Adagen® (pegademase bovine) Carbaglu ™ (carglumic acid) Adcirca® (tadalafil) (ST) (QD) Carimune® NF (immune globulin intravenous [human]) (PA) Advate® (antihemophilic factor [recombinant]) (CPA) Cerezyme® (imiglucerase) (CPA) (ST) Afinitor® (everolimus) (PA) (QD) Cimzia® (certolizumab pegol) (ST) Aldurazyme® (laronidase) (CPA) Copaxone® (glatiramer acetate) (PA) Alphanate® (antihemophilic factor [human]) (CPA) Copegus® (ribavirin) (ST) AlphaNine® SD (coagulation factor IX [human]) (CPA) Corifact® (factor XIII [human]) (CPA) Amevive® (alefacept) (PA) Cystadane® (betaine) Ampyra ™ (dalfampridine) (PA) CytoGam® (cytomegalovirus immune globulin Apokyn® (apomorphine hydrochloride) (PA) (QD) intravenous [human])* (CPA) Aralast® (alpha[1]-proteinase inhibitor [human]) Cytovene® IV (ganciclovir sodium)* Aranesp® (darbepoetin alfa) (PA) Dacogen® (decitabine) Arcalyst® (rilonacept) (PA) (QD) Dysport® (abobotulinumtoxinA) (PA) Arixtra® (fondaparinux sodium)* Egrifta ™ (tesamorelin) (PA) Arranon® (nelarabine) Elaprase® (idursulfase) (CPA) Arzerra® (ofatumumab)
    [Show full text]
  • Hemosil ® Liquid Anti-Xa
    H E M O S I L® LIQUID ANTI-XA Measuring heparin and apixaban: Simple, fast, 24/7 • Liquid formulation, ready-to-use • One-stage, chromogenic anti-Xa assay • Universal calibration for unfractionated heparin (UFH) and low molecular weight heparin (LMWH) • Drug specific calibrators and controls for measurement of apixaban Measuring heparin and apixaban Unfractionated and low molecular weight heparin Heparin is a highly sulfated polysaccharide Laboratory monitoring is extremely important to characterized by a wide molecular weight range and assess the appropriate level of anticoagulation in potent anticoagulant activity. It exists either as UFH patients receiving UFH. Anti-Xa is recommended for or as depolymerized LMWH. UFH and LMWH have measuring both UFH and LMWH. a rapid anticoagulant effect and are used in the prevention and treatment of venous thrombosis and Anti-Xa testing for measuring UFH helps improve acute coronary syndrome. quality of care and patient experience while reducing costs, when compared with APTT testing.1 UFH and LMWH anticoagulant activity occurs when The advantages include: a complex with antithrombin (AT) is formed, • Higher precision potentiating its anticoagulant activity up to • Lower levels of discordant results1,2,4 1,000-fold, which inactivates both thrombin (FIIa) • Faster time to achieve therapeutic levels1,3,4 and Factor Xa (FXa). UFH acts through both FIIa 1,3,4,5 and FXa inhibition, while LMWH is a more efficient • Fewer tests and dosage changes catalyst for FXa inhibition. Direct Xa inhibitors Anticoagulation for patients with venous DOACs do not require routine monitoring. However, thromboembolism (VTE) previously included there are specific instances when an understanding heparin, heparin derivatives and/or oral vitamin K of the DOAC concentration in a patient sample may antagonists.
    [Show full text]
  • New Zealand Data Sheet 1
    New Zealand Data Sheet 1. PRODUCT NAME NAXEN® 250 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each NAXEN 250 mg tablet contains 250 mg of Naproxen For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM NAXEN 250 mg tablets are yellow, biconvex, round tablet of 11 mm diameter with one face engraved NX250 and having a bisecting score. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications NAXEN is indicated in adults for the relief of symptoms associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendonitis and bursitis, acute gout and primary dysmenorrhoea. NAXEN is indicated in children for juvenile arthritis. 4.2. Dose and method of administration After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used (see Section 4.4). During long-term administration the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. A lower daily dose may suffice for long-term administration. In patients who tolerate lower doses well, the dose may be increased to 1000 mg per day when a higher level of anti-inflammatory/analgesic 1 | P a g e activity is required. When treating patients with naproxen 1000 mg/day, the physician should observe sufficient increased clinical benefit to offset the potential increased risk. Dose Adults For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis Initial therapy: The usual dose is 500-1000 mg per day taken in two doses at 12 hour intervals.
    [Show full text]
  • TITLE: Tinzaparin Versus Dalteparin Or Enoxaparin for the Treatment of Venous Thromboembolism in Adults: Safety and Guidelines
    TITLE: Tinzaparin versus Dalteparin or Enoxaparin for the Treatment of Venous Thromboembolism in Adults: Safety and Guidelines DATE: 12 March 2013 RESEARCH QUESTION 1. What is the clinical evidence for the safety of tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism in adults with a glomerular filtration rate (eGFR) less than 30 ml/min? 2. What is the clinical evidence for the safety of tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism in adults who require dialysis? 3. What are the evidence-based guidelines for the use of tinzaparin for adults with venous thromboembolism and a glomerular filtration rate less than 30 mL/min or adults who require dialysis? KEY MESSAGE Two meta-analyses, one randomized controlled trial, and one non-randomized study were identified regarding the safety of tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism. No evidence-based guidelines were identified. METHODS A limited literature search was conducted on key resources including Pubmed, The Cochrane Library (2013, Issue 2), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were applied. Where possible, retrieval was limited to the human population. The search was also limited to documents published between January 1, 2003 and March 1, 2013. Internet links were provided, where available. Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews.
    [Show full text]
  • What You Need to Know About Deep Vein Thrombosis (DVT)
    What You Need to Know About Deep Vein Thrombosis What is a Deep Vein Thrombosis? A deep vein thrombosis (DVT) is a blood clot that forms in the veins in the body (usually in the leg or pelvis). What causes a Deep Vein Thrombosis? Deep vein thrombosis (DVT) sometimes occurs for no apparent reason. However, certain factors can increase the chance of developing a DVT: • Inactivity • Hospital stays and surgery • Damage to your blood vessel from an injury or trauma • Medical and genetic conditions • Pregnancy • Taking estrogen-based medicine such as hormonal birth control or hormone replacement therapy • Overweight or obese • Family history of DVT • Older age What are the symptoms of DVT? Only about half of the people who have a DVT have signs and symptoms. These signs and symptoms of a deep vein clot include: • Pain or tenderness, often starting in the calf. • Swelling, including the ankle & foot. • Warmth and redness of the area or a noticeable discoloration Vascular Surgery -1- How is a DVT diagnosed? Your doctor will ask you questions about your symptoms and if your symptoms suggest that a blood clot is likely, you could have one or all of the following tests: • Blood test for a D-dimer: this test measures the level of a compound released when blood clots are dissolving. A high level may mean you have Deep Vein Thrombosis (DVT). • Imaging studies: o Ultrasound – This is the most common test for diagnosing deep vein blood clots. This test uses sound waves to create pictures of blood flowing through the arteries and veins in the affected leg.
    [Show full text]
  • Perioperative Management of Patients Treated with Antithrombotics in Oral Surgery
    SFCO/Perioperative management of patients treated with antithrombotic agents in oral surgery/Rationale/July 2015 SOCIÉTÉ FRANÇAISE DE CHIRURGIE ORALE [FRENCH SOCIETY OF ORAL SURGERY] IN COLLABORATION WITH THE SOCIÉTÉ FRANÇAISE DE CARDIOLOGIE [FRENCH SOCIETY OF CARDIOLOGY] AND THE PERIOPERATIVE HEMOSTASIS INTEREST GROUP Space Perioperative management of patients treated with antithrombotics in oral surgery. RATIONALE July 2015 P a g e 1 | 107 SFCO/Perioperative management of patients treated with antithrombotic agents in oral surgery/Rationale/July 2015 Abbreviations ACS Acute coronary syndrome(s) ADP Adenosine diphosphate Afib Atrial Fibrillation AHT Arterial hypertension Anaes Agence nationale d’accréditation et d’évaluation en santé [National Agency for Accreditation and Health Care Evaluation] APA Antiplatelet agent(s) aPTT Activated partial thromboplastin time ASA Aspirin BDMP Blood derived medicinal products BMI Body mass index BT Bleeding Time cAMP Cyclic adenosine monophosphate COX-1 Cyclooxygenase 1 CVA Cerebral vascular accident DIC Disseminated intravascular coagulation DOA Direct oral anticoagulant(s) DVT Deep vein thrombosis GEHT Study Group on Hemostasis and Thrombosis (groupe d’étude sur l’hémostase et la thrombose) GIHP Hemostasis and Thrombosis Interest Group (groupe d’intérêt sur l’hémostase et la thrombose) HAS Haute autorité de santé [French Authority for Health] HIT Heparin-induced thrombocytopenia IANB Inferior alveolar nerve block INR International normalized ratio IV Intravenous LMWH Low-molecular-weight heparin(s)
    [Show full text]
  • Drug Interactions and Lethal Drug Combinations
    J Clin Pathol: first published as 10.1136/jcp.28.Suppl_9.94 on 1 January 1975. Downloaded from J. clin. Path., 28, Suppl. (Roy. Coll. Path.), 9, 94-98 The drug dilemma-benefits and hazards Drug interactions and lethal drug combinations ALAN RICHENS From the Department of Clinical Pharmacology, St Bartholomew's Hospital, London Although the development of drugs of greater example, aspirin can displace oral anticoagulants potency and efficacy confers on the physician from their plasma-protein-binding sites, and in- increasing power to treat serious diseases, it also directly acting sympathomimetics contained in cough increases the number and seriousness of potential mixtures can cause a hypertensive crisis in patients adverse effects and drug interactions which can on monoamine oxidase inhibitors. Self-medication is occur. Most hospital patients receive more than one common, and often involves drugs obtained on drug at a time, the average number often being prescription for a previous illness. greater than five (Smith, Seidl, and Cluff, 1966). The 4 When several clinics or doctors are involved in incidence of drug reactions rises with the number of the care of a patient, one doctor may not be aware of drugs prescribed simultaneously. In patients pre- what another has prescribed. scribed one to five drugs the incidence of reactions is 5 When preparations which contain more than 18-6%, while in patients prescribed six or more one ingredient are prescribed by their trade names. it rises to 814 % (Hurwitz and Wade, 1969). There are a number of ways in which drugs may The Boston Collaborative Drug Surveillance interact.
    [Show full text]
  • Innohep® Is and What It Is Used for • If You Have Kidney Problems
    Scale Get-up Material No Sent by e-maiL l 5. RBE 100% GB 066478-XX Subject Date Date 14/09/20 066478 INS 205 x 315 mm with 2 foils 27/05/20 066478-XX Colour Sign. Sign. SOP_000647, SOP_000962, SOP_000647, SOP_000962 Black OMA SOP_003993 and and SOP_008676 SOP_008676 Preparation Place of production Strength ® Packsize innohep syringe 20,000 IU/ml France Comments: Page 1 of 2 Font size: 9 pt Headings 10 pt Mock-up for reg. purpose IFR012-01 - 205 x 315 mm Page 4 of 4 Page 1 of 4 066478-XX Package leaflet: Information for the user syringe 20,000 IU/ml tinzaparin sodium Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. 066478 • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. • In this leaflet innohep 20,000 IU/ml syringe will be called innohep. What is in this leaflet • If you have an artificial heart valve. 1. What innohep® is and what it is used for • If you have kidney problems. 2. What you need to know before you use innohep® • If you have asthma, as this medicine contains sodium 3.
    [Show full text]
  • Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management
    Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management Green-top Guideline No. 37b April 2015 Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management This is the third edition of this guideline. The first edition was published in April 2001 under the same title (numbered Green-top Guideline No. 28) and the second edition was published in February 2007 and reviewed in 2010. Thromboprophylaxis during pregnancy and the puerperium is addressed in Green-top Guideline No. 37a. Executive summary of recommendations Diagnosis of acute venous thromboembolism (VTE) How is acute VTE diagnosed in pregnancy? Any woman with symptoms and/or signs suggestive of VTE should have objective testing performed C expeditiously and treatment with low-molecular-weight heparin (LMWH) given (see section 6) until the diagnosis is excluded by objective testing, unless treatment is strongly contraindicated. Individual hospitals should have an agreed protocol for the objective diagnosis of suspected VTE during pregnancy. This may recommend the involvement of obstetricians, radiologists, physicians P and haematologists. What investigations are needed for the diagnosis of an acute DVT? Compression duplex ultrasound should be undertaken where there is clinical suspicion of DVT. B If ultrasound is negative and there is a low level of clinical suspicion, anticoagulant treatment can C be discontinued. If ultrasound is negative and a high level of clinical suspicion exists, anticoagulant treatment should be discontinued but the ultrasound should be repeated on days 3 and 7. [New 2015] What investigations are needed for the diagnosis of an acute pulmonary embolism (PE)? Women presenting with symptoms and signs of an acute PE should have an electrocardiogram C (ECG) and a chest X-ray (CXR) performed.
    [Show full text]
  • Dicoumarol: a Unique Microtubule Stabilizing Natural Product That Is Synergistic with Taxol1
    [CANCER RESEARCH 63, 1214–1220, March 15, 2003] Dicoumarol: A Unique Microtubule Stabilizing Natural Product that Is Synergistic with Taxol1 Hamta Madari, Dulal Panda, Leslie Wilson, and Robert S. Jacobs2 Departments of Ecology, Evolution, and Marine Biology [H. M., R. S. J.] and Molecular, Cellular, and Developmental Biology [L. W.], University of California, Santa Barbara, California 93106, and Bhupat and Jyoti Mehta School of Biosciences and Bioengineering, Indian Institute of Technology, Bombay, Mumbai, India 400076 [D. P.] ABSTRACT prostate cancer, malignant melanoma, and metastatic renal cell carci- noma (12–14). In studies on the antiproliferative actions of coumarin compounds, we In addition, the coumarin anticoagulants, dicoumarol (Dicumarol) -discovered that dicoumarol (a coumarin anticoagulant; 3,3؅-methyl and its synthetic derivative warfarin sodium (Coumadin), have been enebis[4-hydroxycoumarin]) inhibits the first cleavage of Strongylocentro- tus purpuratus (sea urchin) embryos in a concentration-dependent manner shown to decrease metastases in experimental animals (15). Warfarin with 50% inhibition occurring at a concentration of 10 ␮M. Because first sodium, largely replacing dicoumarol therapeutically as an anticoag- cleavage in sea urchin embryos is highly selective for microtubule- ulant, has been used for the treatment of a variety of cancers and targeted agents, we thought that the active compounds might inhibit cell shown to improve tumor response rates and survival in patients with division by interacting with tubulin or microtubules. We found that several types of cancer (16–22). However, despite numerous studies, ␮ dicoumarol binds to bovine brain tubulin with a Kd of 22 M and that 0.1 little information has been acquired on the cellular mechanism of ␮ M dicoumarol strongly stabilizes the growing and shortening dynamics action of coumarin compounds in the treatment of malignancies.
    [Show full text]